UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma (Nasdaq: URGN) has announced inducement grants of restricted stock units (RSUs) to 40 new employees. The grants, which can result in the issuance of up to 67,700 ordinary shares, are designed to support the commercialization of their approved products Jelmyto® and ZUSDURI™, as well as pipeline development.
The RSUs will vest equally over three years, with one-third vesting annually on the anniversary of the vesting date, contingent on continued employment. These grants were made under UroGen's 2019 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
UroGen Pharma (Nasdaq: URGN) ha annunciato l'assegnazione, a titolo di incentivo, di unità azionarie vincolate (RSU) a 40 nuovi dipendenti. Le assegnazioni, che potrebbero tradursi nell'emissione di fino a 67.700 azioni ordinarie, sono pensate per supportare la commercializzazione dei prodotti approvati Jelmyto® e ZUSDURI™, oltre allo sviluppo della pipeline.
Le RSU matureranno in parti uguali nell'arco di tre anni, con un terzo che matura ogni anno nella ricorrenza della data di maturazione, subordinatamente alla permanenza in servizio. Queste assegnazioni sono state effettuate ai sensi del Piano di Indennizzo 2019 di UroGen, in conformità alla Regola di Quotazione Nasdaq 5635(c)(4).
UroGen Pharma (Nasdaq: URGN) ha anunciado concesiones de unidades de acciones restringidas (RSU) como incentivo a 40 nuevos empleados. Las concesiones, que podrían dar lugar a la emisión de hasta 67.700 acciones ordinarias, están destinadas a respaldar la comercialización de sus productos aprobados Jelmyto® y ZUSDURI™, así como el desarrollo de la cartera de proyectos.
Las RSU vencerán por partes iguales en tres años, con un tercio que vence cada año en el aniversario de la fecha de adquisición, condicionado a la continuidad en el empleo. Estas concesiones se realizaron en el marco del Plan de Inducción 2019 de UroGen, de conformidad con la Norma de Cotización Nasdaq 5635(c)(4).
UroGen Pharma (나스닥: URGN)는 40명의 신규 직원에게 유인성 제한주식단위(RSU)를 부여한다고 발표했습니다. 이 부여는 최대 67,700 보통주 발행으로 이어질 수 있으며, 승인된 제품 Jelmyto®와 ZUSDURI™의 상업화 및 파이프라인 개발을 지원하기 위한 것입니다.
RSU는 3년에 걸쳐 동일하게 베스팅되며, 베스팅일 기념일에 매년 1/3씩 베스팅되며 계속 근무 조건이 충족되어야 합니다. 이 부여는 나스닥 상장규정 5635(c)(4)에 따라 UroGen의 2019 유인계획(Inducement Plan) 하에서 이루어졌습니다.
UroGen Pharma (Nasdaq : URGN) a annoncé des attributions incitatives d'unités d'actions restreintes (RSU) à 40 nouveaux employés. Ces attributions, pouvant entraîner l'émission de jusqu'à 67 700 actions ordinaires, visent à soutenir la commercialisation de leurs produits approuvés Jelmyto® et ZUSDURI™, ainsi que le développement de la pipeline.
Les RSU seront acquises à parts égales sur trois ans, un tiers étant acquis chaque année à la date anniversaire de l'attribution, sous réserve de la continuité de l'emploi. Ces attributions ont été effectuées dans le cadre du Inducement Plan 2019 d'UroGen, conformément à la règle de cotation Nasdaq 5635(c)(4).
UroGen Pharma (Nasdaq: URGN) hat Anreizzusagen in Form von Restricted Stock Units (RSUs) an 40 neue Mitarbeiter bekannt gegeben. Die Zuweisungen, die zur Ausgabe von bis zu 67.700 Stammaktien führen können, sollen die Kommerzialisierung der zugelassenen Produkte Jelmyto® und ZUSDURI™ sowie die Weiterentwicklung der Pipeline unterstützen.
Die RSUs werden über drei Jahre gleichmäßig vesten, wobei jeweils ein Drittel jährlich am Jahrestag des Vesting-Datums vestet, abhängig von fortgesetzter Beschäftigung. Die Zuweisungen erfolgten im Rahmen des Inducement Plans von UroGen aus 2019 gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Expansion of workforce with 40 new employees to support commercialization efforts
- Strategic alignment of employee incentives with company growth through equity compensation
- Potential dilution of existing shareholders through issuance of up to 67,700 new shares
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 40 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.
Up to 67,700 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.
The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. To learn more, visit www.urogen.com or follow us on X (Twitter), @UroGenPharma.
Jelmyto®, RTGel®, ZUSDURI™ and UroGen® are registered trademarks of UroGen Pharma Ltd.
INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588
MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3583
FAQ
How many RSUs did UroGen Pharma (URGN) grant to new employees in September 2025?
What is the vesting schedule for UroGen's (URGN) September 2025 RSU grants?
What products will the new UroGen (URGN) employees support?
Under which Nasdaq rule were UroGen's (URGN) September 2025 RSU grants made?
